Ruxolitinib (RUX) cream demonstrated potent anti-inflammatory and antipruritic efficacy in a phase 2 study in adults with atopic dermatitis (AD).To evaluate 8-week efficacy and safety in two phase 3 studies […]
-
-
Can dermatology employers require employees to receive the COVID-19 vaccine?
-
THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS
-
Expression of retinoid receptors in hand eczema.
-
S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants
-
Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.
